Viewing Study NCT03244956

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 11:30 PM
Ignite Modification Date: 2026-01-24 @ 1:55 PM
Study NCT ID: NCT03244956
Status: UNKNOWN
Last Update Posted: 2021-09-28
First Post: 2017-08-07
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer
Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or … View
Keywords: